Dr. Ronald L. Paquette
Claim this profileCedars-Sinai Medical Center
Studies Hematological Malignancies
Studies Blood Cancers
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Ronald L. Paquette is currently running
Cyclophosphamide After Stem Cell Transplant
for Blood Cancer
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Recruiting1 award Phase 1
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
More about Ronald L. Paquette
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ronald L. Paquette has experience with
- Cyclophosphamide
- Daratumumab/rHuPH20
- Lenalidomide
- Blinatumomab
- Haplo-Mismatched Cell Therapy (HMCT)
- Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy
Breakdown of trials Ronald L. Paquette has run
Hematological Malignancies
Blood Cancers
Multiple Myeloma
Acute Lymphoblastic Leukemia
Plasma Cell Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ronald L. Paquette specialize in?
Ronald L. Paquette focuses on Hematological Malignancies and Blood Cancers. In particular, much of their work with Hematological Malignancies has involved treating patients, or patients who are undergoing treatment.
Is Ronald L. Paquette currently recruiting for clinical trials?
Yes, Ronald L. Paquette is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Ronald L. Paquette has studied deeply?
Yes, Ronald L. Paquette has studied treatments such as Cyclophosphamide, Daratumumab/rHuPH20, Lenalidomide.
What is the best way to schedule an appointment with Ronald L. Paquette?
Apply for one of the trials that Ronald L. Paquette is conducting.
What is the office address of Ronald L. Paquette?
The office of Ronald L. Paquette is located at: Cedars-Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars-Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.